Fwd: Chest CT of Incidental Breast Lesions.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: Chest CT of Incidental Breast Lesions.
To: mesothelioma77@gmail.com


[1]J Thorac Imaging. 2008 May; 23(2): 148-155
Yi JG, Kim SJ, Marom EM, Park JH, Jung SI, Lee MW

Chest computed tomography (CT) is routinely used for the evaluation of diseases of the chest involving the lung, mediastinum, pleura, chest wall, and diaphragm. Benign and malignant breast lesions are not uncommonly encountered incidentally on chest CT. The chest CT radiologist should be aware of the different breast pathologies and their CT appearances as some can be diagnosed by chest CT, whereas others, such as breast cancer, should not be overlooked. The purpose of this pictorial essay is to show various common and uncommon breast conditions encountered while interpreting chest CT scans in our daily practice.



___
Source: http://www.hubmed.org/display.cgi?uids=18520577
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jun 5, 2008 at 1:34 AM
Subject: Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 4;
Potter SM, Dwyer RM, Curran CE, Hennessy E, Harrington KA, Griffin DG, Kerin MJ

Introduction The chemokines Stromal Cell-Derived Factor-1alpha (SDF-1alpha/CXCL12) and Monocyte Chemotactic Protein-1 (MCP-1/CCL2) have been implicated in breast cancer progression. We recently reported elevated systemic MCP-1 in breast cancer patients. This study investigated circulating levels of SDF-1alpha in breast cancer patients, and addressed potential hormonal regulation of these two potent chemokines. Methods SDF-1alpha levels were determined by ELISA in 114 breast cancer patients and 85 controls, and correlated with clinical data. Blood samples were collected from 36 healthy premenopausal volunteers weekly for four weeks to measure Luteinising Hormone (LH), Follicular Stimulating Hormone (FSH), Oestradiol and Progesterone using a Bayer ADVIA((R)) Centaur Immunoassay system, in parallel with SDF-1alpha and MCP-1. CXCL12 expression was determined using RQ-PCR in primary tumour stromal cells (n = 16) harvested at surgery. Results Plasma SDF-1alpha was significantly higher in breast cancer patients than age-matched controls and had a significant correlation with tumour grade and epithelial subtype. Investigation of menstrual variations of these chemokines revealed lower SDF-1alpha levels in the mid-luteal phase of the menstrual cycle and a significant positive correlation with circulating Oestradiol. MCP-1 levels showed no correlation with menstrual hormones. There was a trend towards increased CXCL12 expression in tumour compared to normal stromal cells. Conclusions The elevated level of SDF-1alpha detected in breast cancer patients, and it's correlation with prognostic indicators, highlights the importance of this chemokine in disease progression. Elucidation of factors influencing chemokine secretion supports clarification of their role in tumourigenesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18521742
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc